Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis
View ORCID ProfileCaroline Korves, Hector S. Izurieta, Jeremy Smith, Gabrielle M. Zwain, Ethan I. Powell, Abirami Balajee, Kathryn Ryder, Yinong Young-Xu
doi: https://doi.org/10.1101/2022.03.17.22272555
Caroline Korves
1White River Junction Veterans Affairs Medical Center, White River Junction, VT
ScDHector S. Izurieta
2Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, White Oak, MD
MD, MPH, PhDJeremy Smith
1White River Junction Veterans Affairs Medical Center, White River Junction, VT
MSGabrielle M. Zwain
1White River Junction Veterans Affairs Medical Center, White River Junction, VT
BAEthan I. Powell
1White River Junction Veterans Affairs Medical Center, White River Junction, VT
BAAbirami Balajee
1White River Junction Veterans Affairs Medical Center, White River Junction, VT
MPH, BS, BAKathryn Ryder
3Veterans Affairs Pacific Island Health Care
MD, MSYinong Young-Xu
1White River Junction Veterans Affairs Medical Center, White River Junction, VT
4Geisel School of Medicine at Dartmouth, Hanover, NH
ScD, MA, MSData Availability
Because data contain potentially identifying or sensitive patient information, all relevant data must be requested through the Department of Veterans Affairs at: Research and Development Committee VA Medical Center 163 Veterans Drive White River Junction, VT 05009-0001
Posted March 30, 2022.
Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis
Caroline Korves, Hector S. Izurieta, Jeremy Smith, Gabrielle M. Zwain, Ethan I. Powell, Abirami Balajee, Kathryn Ryder, Yinong Young-Xu
medRxiv 2022.03.17.22272555; doi: https://doi.org/10.1101/2022.03.17.22272555
Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis
Caroline Korves, Hector S. Izurieta, Jeremy Smith, Gabrielle M. Zwain, Ethan I. Powell, Abirami Balajee, Kathryn Ryder, Yinong Young-Xu
medRxiv 2022.03.17.22272555; doi: https://doi.org/10.1101/2022.03.17.22272555
Subject Area
Subject Areas
- Addiction Medicine (403)
- Allergy and Immunology (712)
- Anesthesia (206)
- Cardiovascular Medicine (2968)
- Dermatology (252)
- Emergency Medicine (445)
- Epidemiology (12803)
- Forensic Medicine (12)
- Gastroenterology (830)
- Genetic and Genomic Medicine (4617)
- Geriatric Medicine (423)
- Health Economics (732)
- Health Informatics (2941)
- Health Policy (1072)
- Hematology (393)
- HIV/AIDS (932)
- Medical Education (430)
- Medical Ethics (116)
- Nephrology (475)
- Neurology (4403)
- Nursing (238)
- Nutrition (648)
- Oncology (2292)
- Ophthalmology (651)
- Orthopedics (260)
- Otolaryngology (327)
- Pain Medicine (280)
- Palliative Medicine (84)
- Pathology (502)
- Pediatrics (1199)
- Primary Care Research (502)
- Public and Global Health (6997)
- Radiology and Imaging (1542)
- Respiratory Medicine (920)
- Rheumatology (444)
- Sports Medicine (386)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)